<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04083170</url>
  </required_header>
  <id_info>
    <org_study_id>RG1004070</org_study_id>
    <secondary_id>NCI-2019-05729</secondary_id>
    <secondary_id>R34HL142322</secondary_id>
    <secondary_id>10304</secondary_id>
    <nct_id>NCT04083170</nct_id>
  </id_info>
  <brief_title>Cord Blood Transplant With OTS for the Treatment of HIV Positive Hematologic Cancers</brief_title>
  <official_title>Infusion of Off-the-Shelf Ex Vivo Expanded Cryopreserved Progenitor Cells to Facilitate the Engraftment of a Single CCR5Î”32 Homozygous or Heterozygous Cord Blood Unit in Patients With HIV and Hematological Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies the side effects of a cord blood transplant using OTS and to see&#xD;
      how well it works in treating patients with human immunodeficiency virus (HIV) positive&#xD;
      hematologic (blood) cancers. After a cord blood transplant, the immune cells, including white&#xD;
      blood cells, can take a while to recover, putting the patient at increased risk of infection.&#xD;
      OTS consists of blood stem cells that help to produce mature blood cells, including immune&#xD;
      cells. Drugs used in chemotherapy, such as fludarabine, cyclophosphamide, and thiotepa, work&#xD;
      in different ways to stop the growth of tumor cells, either by killing the cells, by stopping&#xD;
      them from dividing, or by stopping them from spreading. Total body irradiation is a type of&#xD;
      whole-body radiation. Giving chemotherapy and total-body irradiation before a cord blood&#xD;
      transplant with OTS may help to kill any cancer cells that are in the body and make room in&#xD;
      the patient's bone marrow for new stem cells to grow and reduce the risk of infection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OUTLINE: Patients are assigned to 1 of 2 regimens.&#xD;
&#xD;
      REGIMEN A: Patients receive fludarabine intravenously (IV) over 30 minutes on days -8 to -6,&#xD;
      cyclophosphamide IV on days -7 to -6, and undergo total body irradiation (TBI) twice daily&#xD;
      (BID) on days -4 to -1. Patients then undergo umbilical cord blood transplant on day 0.&#xD;
      Between 4-24 hours after transplant completion, patients receive umbilical cord blood-derived&#xD;
      hematopoietic CD34-positive progenitor cells IV over 5-10 minutes in the absence of disease&#xD;
      progression or unacceptable toxicity.&#xD;
&#xD;
      REGIMEN B: Patients receive fludarabine IV over 30-60 minutes on days -6 to -2,&#xD;
      cyclophosphamide IV on day -6, thiotepa IV over 4 hours on days -5 to -4, and undergo TBI&#xD;
      once daily (QD) on days -2 to -1. Patients then undergo umbilical cord blood transplant on&#xD;
      day 0. Between 4-24 hours after transplant completion, patients receive umbilical cord&#xD;
      blood-derived hematopoietic CD34-positive progenitor cells IV over 5-10 minutes in the&#xD;
      absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up at 28, 80, and 180 days, and&#xD;
      then at 1 and 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 18, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary graft failure rejection</measure>
    <time_frame>Up to day 45</time_frame>
    <description>Will be defined by no neutrophil recovery by day 45 (regardless of donor chimerism) or autologous recovery (neutrophil recovery but &lt; 10% donor chimerism in blood and bone marrow) by day 45.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of infusion toxicities</measure>
    <time_frame>Within the first 24 hours after infusion</time_frame>
    <description>Defined as Common Terminology Criteria for Adverse Events version 5.0 grade &gt;= 3 events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neutrophil recovery</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Will be defined as the first day of 2 consecutive days of absolute neutrophil count &gt;= 500 after the first post-cord blood transplant nadir.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet engraftment</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Will be defined as the first day of a platelet count &gt; 20,000/ul with subsequent transfusions for 7 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe (grades III-IV) acute graft versus host disease (GVHD)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Will be defined by the 2014 National Institutes of Health (NIH) criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chronic GVHD</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Will be defined by the 2014 NIH criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-relapse mortality</measure>
    <time_frame>Up to day 180</time_frame>
    <description>Will be defined as death without a prior relapse.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Acute Erythroid Leukemia</condition>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <condition>Acute Megakaryoblastic Leukemia</condition>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Chronic Myelogenous Leukemia, BCR-ABL1 Positive</condition>
  <condition>Hematopoietic and Lymphoid Cell Neoplasm</condition>
  <condition>HIV Infection</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <condition>Myelodysplastic Syndrome With Excess Blasts</condition>
  <condition>Non-Hodgkin Lymphoma</condition>
  <condition>Refractory Anemia</condition>
  <arm_group>
    <arm_group_label>Regimen A (fludarabine, cyclophosphamide, TBI, OTS)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive fludarabine IV over 30 minutes on days -8 to -6, cyclophosphamide IV on days -7 to -6, and undergo TBI BID on days -4 to -1. Patients then undergo umbilical cord blood transplant on day 0. Between 4-24 hours after transplant completion, patients receive umbilical cord blood-derived hematopoietic CD34-positive progenitor cells IV over 5-10 minutes in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen B (fludarabine, cyclophosphamide, thiotepa, TBI, OTS)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive fludarabine IV over 30-60 minutes on days -6 to -2, cyclophosphamide IV on day -6, thiotepa IV over 4 hours on days -5 to -4, and undergo TBI QD on days -2 to -1. Patients then undergo umbilical cord blood transplant on day 0. Between 4-24 hours after transplant completion, patients receive umbilical cord blood-derived hematopoietic CD34-positive progenitor cells IV over 5-10 minutes in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Regimen A (fludarabine, cyclophosphamide, TBI, OTS)</arm_group_label>
    <arm_group_label>Regimen B (fludarabine, cyclophosphamide, thiotepa, TBI, OTS)</arm_group_label>
    <other_name>118218</other_name>
    <other_name>2-Fluoro-9-beta-arabinofuranosyladenine</other_name>
    <other_name>2-Fluorovidarabine</other_name>
    <other_name>9-Beta-D-arabinofuranosyl-2-fluoroadenine</other_name>
    <other_name>Fluradosa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Regimen A (fludarabine, cyclophosphamide, TBI, OTS)</arm_group_label>
    <arm_group_label>Regimen B (fludarabine, cyclophosphamide, thiotepa, TBI, OTS)</arm_group_label>
    <other_name>Carloxan</other_name>
    <other_name>Ciclofosfamida</other_name>
    <other_name>Ciclofosfamide</other_name>
    <other_name>Cicloxal</other_name>
    <other_name>Clafen</other_name>
    <other_name>Claphene</other_name>
    <other_name>CP monohydrate</other_name>
    <other_name>CTX</other_name>
    <other_name>CYCLO-cell</other_name>
    <other_name>Cycloblastin</other_name>
    <other_name>Cycloblastine</other_name>
    <other_name>Cyclophospham</other_name>
    <other_name>Cyclophosphamid monohydrate</other_name>
    <other_name>Cyclophosphamide Monohydrate</other_name>
    <other_name>Cyclophosphamidum</other_name>
    <other_name>Cyclophosphan</other_name>
    <other_name>Cyclostin</other_name>
    <other_name>Cyclostine</other_name>
    <other_name>Cytophosphan</other_name>
    <other_name>Cytophosphane</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Fosfaseron</other_name>
    <other_name>Genoxal</other_name>
    <other_name>Genuxal</other_name>
    <other_name>Ledoxina</other_name>
    <other_name>Mitoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thiotepa</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Regimen B (fludarabine, cyclophosphamide, thiotepa, TBI, OTS)</arm_group_label>
    <other_name>STEPA</other_name>
    <other_name>Tepadina</other_name>
    <other_name>TESPA</other_name>
    <other_name>Tespamin</other_name>
    <other_name>Tespamine</other_name>
    <other_name>Thiofosfamide</other_name>
    <other_name>Thio-Tepa</other_name>
    <other_name>Thiofozil</other_name>
    <other_name>Thiophosphamide</other_name>
    <other_name>Thiophosphoramide</other_name>
    <other_name>Thiotef</other_name>
    <other_name>Tifosyl</other_name>
    <other_name>Triethylene thiophosphoramide</other_name>
    <other_name>Triethylenethiophosphoramide</other_name>
    <other_name>TSPA</other_name>
    <other_name>WR 45312</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Total-Body Irradiation</intervention_name>
    <description>Undergo TBI</description>
    <arm_group_label>Regimen A (fludarabine, cyclophosphamide, TBI, OTS)</arm_group_label>
    <arm_group_label>Regimen B (fludarabine, cyclophosphamide, thiotepa, TBI, OTS)</arm_group_label>
    <other_name>TBI</other_name>
    <other_name>TOTAL BODY IRRADIATION</other_name>
    <other_name>Whole Body Irradiation</other_name>
    <other_name>Whole-Body Irradiation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Umbilical Cord Blood Transplantation</intervention_name>
    <description>Undergo UCBT</description>
    <arm_group_label>Regimen A (fludarabine, cyclophosphamide, TBI, OTS)</arm_group_label>
    <arm_group_label>Regimen B (fludarabine, cyclophosphamide, thiotepa, TBI, OTS)</arm_group_label>
    <other_name>Cord Blood Transplantation</other_name>
    <other_name>UCB transplantation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cellular Therapy</intervention_name>
    <description>Given OTS IV</description>
    <arm_group_label>Regimen A (fludarabine, cyclophosphamide, TBI, OTS)</arm_group_label>
    <arm_group_label>Regimen B (fludarabine, cyclophosphamide, thiotepa, TBI, OTS)</arm_group_label>
    <other_name>Cell Therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Treatment with combination antiretroviral therapy (cART) for at least 1 month before&#xD;
             enrollment&#xD;
&#xD;
          -  Viral load &lt; 5000 copies/ml plasma on cART&#xD;
&#xD;
          -  Disease criteria&#xD;
&#xD;
               -  Acute myeloid leukemia&#xD;
&#xD;
                    -  High risk in first complete remission (CR1), &gt;= 2 cycles to obtain complete&#xD;
                       remission (CR), erythroblastic or megakaryocytic leukemia; &gt;= in second&#xD;
                       complete remission (CR2)&#xD;
&#xD;
                    -  All patients must be in CR as defined by hematologic recovery and &lt; 5%&#xD;
                       blasts by morphology within the bone marrow and a cellularity of &gt;= 15%&#xD;
&#xD;
                    -  Patients for whom adequate marrow/biopsy specimens cannot be obtained to&#xD;
                       determine remission status by morphologic assessment, but have fulfilled&#xD;
                       criteria of remission by flow cytometry, recovery of peripheral blood counts&#xD;
                       with no circulating blasts, and/or normal cytogenetics (if applicable) may&#xD;
                       still be eligible. Specimen for morphologic assessment, including possible&#xD;
                       repeat procedures will be obtained (as possible). These patients must be&#xD;
                       discussed with the lead principal investigator, Filippo Milano prior to&#xD;
                       enrollment&#xD;
&#xD;
               -  Acute lymphoblastic leukemia&#xD;
&#xD;
                    -  High risk CR1 (for example, but not limited to: t(9;22), t(1;19), t(4;11) or&#xD;
                       other mixed-lineage leukemia [MLL] rearrangements, hypodiploid); greater&#xD;
                       than 1 cycle to obtain CR; &gt;= CR2&#xD;
&#xD;
                    -  All patients must be in CR as defined by hematologic recovery and &lt; 5%&#xD;
                       blasts by morphology within the bone marrow and a cellularity of &gt;= 15%&#xD;
&#xD;
                    -  Patients in which adequate marrow/biopsy specimens cannot be obtained to&#xD;
                       determine remission status by morphologic assessment, but have fulfilled&#xD;
                       criteria of remission by flow cytometry, recovery of peripheral blood counts&#xD;
                       with no circulating blasts, and/or normal cytogenetics (if applicable) may&#xD;
                       still be eligible. Specimen for morphologic assessment, including possible&#xD;
                       repeat procedures will be obtained (as possible). These patients must be&#xD;
                       discussed with the lead principal investigator, Filippo Milano prior to&#xD;
                       enrollment&#xD;
&#xD;
               -  Chronic myelogenous leukemia excluding refractory blast crisis. To be eligible in&#xD;
                  first chronic phase (CP1) patient must have failed or be intolerant to imatinib&#xD;
                  mesylate&#xD;
&#xD;
               -  Myelodysplasia (MDS) International Prognostic Scoring System (IPSS) intermediate&#xD;
                  (Int)-2 or high risk (i.e., refractory anemia with excess blasts [RAEB],&#xD;
                  refractory anemia with excess blasts in transformation [RAEBt]) or refractory&#xD;
                  anemia with severe pancytopenia or high-risk cytogenetics. Blasts must be &lt; 10%&#xD;
                  by a representative bone marrow aspirate morphology&#xD;
&#xD;
               -  Other hematologic malignancy such as non-Hodgkin lymphomas. Fred Hutch site:&#xD;
                  These patients must be presented at Patient Care Conference (PCC) prior to&#xD;
                  enrollment, given potential competing eligibility on auto-transplant protocols.&#xD;
                  Participating centers: These patients must be discussed with the lead principal&#xD;
                  investigator, Filippo Milano prior to enrollment&#xD;
&#xD;
          -  Karnofsky (&gt;= 16 years old) &gt;= 70%&#xD;
&#xD;
          -  Lansky (&lt; 16 years old) &gt;= 50%&#xD;
&#xD;
          -  Adults: Calculated creatinine clearance must be &gt; 60 mL and serum creatinine =&lt; 2&#xD;
             mg/dL&#xD;
&#xD;
          -  Children (&lt; 18 years old): Calculated creatinine clearance must be &gt; 60 mL/min&#xD;
&#xD;
          -  Total serum bilirubin must be &lt; 3 mg/dL&#xD;
&#xD;
          -  Transaminases must be &lt; 3 x the upper limit of normal&#xD;
&#xD;
          -  Diffusion capacity of the lung for carbon monoxide (DLCO) corrected &gt; 50% normal or&#xD;
             for pediatric patients in whom DLCO cannot be measured has adequate pulmonary function&#xD;
&#xD;
          -  Left ventricular ejection fraction &gt; 45% OR&#xD;
&#xD;
          -  Shortening fraction &gt; 26%&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document&#xD;
             (adult subject or parent/legal guardian of minor subject)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Uncontrolled viral or bacterial infection at the time of study enrollment&#xD;
&#xD;
          -  Active or recent (prior 6 month) invasive fungal infection without infectious disease&#xD;
             (ID) consult and approval&#xD;
&#xD;
          -  Pregnant or breastfeeding&#xD;
&#xD;
          -  Prior myeloablative transplant within the last 6 months&#xD;
&#xD;
          -  Extensive prior therapy including &gt; 12 months alkylator therapy or &gt; 6 months&#xD;
             alkylator therapy with extensive radiation&#xD;
&#xD;
          -  Central nervous system (CNS) leukemic involvement not clearing with intrathecal&#xD;
             chemotherapy. Diagnostic lumbar puncture to be performed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Filippo Milano</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutch/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Filippo Milano</last_name>
    <phone>206.667.5925</phone>
    <email>fmilano@fredhutch.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Timothy Henrich</last_name>
      <email>Timothy.Henrich@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Timothy Henrich</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Blachy Saldana</last_name>
      <email>BJDAVILA@childrensnational.org</email>
    </contact>
    <investigator>
      <last_name>Blachy Saldana</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Case Western Reserve University</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kirsten Boughan</last_name>
      <email>Kirsten.Boughan@UHhospitals.org</email>
    </contact>
    <investigator>
      <last_name>Kirsten Boughan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fred Hutch/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Filippo Milano</last_name>
      <phone>206-667-5925</phone>
      <email>fmilano@fredhutch.org</email>
    </contact>
    <investigator>
      <last_name>Filippo Milano</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 6, 2019</study_first_submitted>
  <study_first_submitted_qc>September 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2019</study_first_posted>
  <last_update_submitted>October 18, 2021</last_update_submitted>
  <last_update_submitted_qc>October 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Leukemia, Megakaryoblastic, Acute</mesh_term>
    <mesh_term>Leukemia, Erythroblastic, Acute</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Anemia, Refractory</mesh_term>
    <mesh_term>Anemia, Refractory, with Excess of Blasts</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vidarabine</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Thiotepa</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

